Claro Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Claro Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$717K	Sell	1,606 -99	-6%	-$46.2K	0.09%	186
2025 Q4	$773K	Sell	1,705 -13	-0.8%	-$5.6K	0.11%	171
2025 Q3	$673K	Sell	1,718 -828	-33%	-$346K	0.1%	179
2025 Q2	$1.13M	Sell	2,546 -392	-13%	-$181K	0.19%	104
2025 Q1	$1.42M	Sell	2,938 -137	-4%	-$63.8K	0.19%	97
2024 Q4	$1.24M	Buy	3,075 +650	+27%	+$301K	0.17%	110
2024 Q3	$1.13M	Buy	2,425 +471	+24%	+$226K	0.15%	135
2024 Q2	$916K	Buy	1,954 +591	+43%	+$257K	0.14%	142
2024 Q1	$570K	Buy	1,363 +98	+8%	+$41.4K	0.1%	215
2023 Q4	$515K	Buy	1,265 +56	+5%	+$20.7K	0.11%	210
2023 Q3	$420K	Buy	1,209 +143	+13%	+$50K	0.11%	221
2023 Q2	$375K	Buy	+1,066	New	+$359K	0.09%	235
2019 Q1	–	Sell	-343	Closed	-$66K	–	920
2018 Q4	$66K	Buy	+343	New	+$59.4K	0.05%	296

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Claro Advisors's VRTX Position: Q1 2026 in Review

Claro Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.8% in Q1 2026, selling an estimated $46.2K and leaving 1,606 shares worth $717K. The position accounts for 0.09% of the portfolio, ranked #186.

Claro Advisors first reported a position in VRTX in Q4 2018 and has held it in 13 quarters since. The position peaked at $1.42M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Claro Advisors held 1,606 shares of Vertex Pharmaceuticals worth $717K as of Q1 2026.
Claro Advisors sold 99 Vertex Pharmaceuticals shares in Q1 2026, an estimated $46.2K.
Vertex Pharmaceuticals made up 0.09% of Claro Advisors's portfolio in Q1 2026, its #186 holding.
Claro Advisors first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 13 quarters since.
Claro Advisors's Vertex Pharmaceuticals position peaked at $1.42M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Claro Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.